ARS PHARMACEUTICALS INCSPRY
ASignal's systematic analysis rates SPRY as Bearish.
Reflects the latest available analysis · analyzed Sep 28, 2026
The case on SPRY
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- High revenue growth (114.2%) indicating strong top-line expansion
- Gross margin of 58.35% suggesting pricing power or efficient cost structure
- Current ratio of 3.48x and quick ratio of 3.15x indicating strong short-term liquidity
- RSI near oversold territory (32.02) may suggest downside exhaustion
- Negative operating and net margins (operating margin: -182.62%, net margin: -184.24%)
- Negative return on equity (-210.35%) and return on assets (-48.02%)
- High debt-to-equity ratio (13.72x) raising financial risk concerns
- Negative free cash flow ($-117.7M) and operating cash flow ($-196.4M)
- EV/EBITDA of -2.17x indicating unprofitability
- No Reddit mentions, suggesting low retail investor interest or visibility
See the full verdict on SPRY
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes SPRY
Most investors never get a second opinion, let alone several. ASignal runs SPRY past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.